Johnson & Johnson just listed out the drugs it plans to file for approval over the next few years that could be "blockbusters."
ADVERTISEMENT
The world's largest drugmaker thinks it has 11 billion-dollar drugs in the pipeline — here's what they treat (JNJ)
Johnson & Johnson outlined 11 drugs it plans to file for approval that could have blockbuster sales potential.
J&J CEO Alex Gorsky - Wednesday afternoon
These are drugs that haven't been approved yet, but by 2021, they could be making more than $1 billion in annual sales each.
Right now, the world's largest drugmaker is known for its immunology drugs like Remicade, which made $4.8 billion in sales in 2016 and Stelara, as well as the bloodthinner Xarelto, which made $2.2 billion in sales in 2016.
Here's the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:
ADVERTISEMENT
- guselkumab
- sirukumab
- apalutamide -
- esketamine
- talacotuzumab -
- erdafitinib
- niraparib
- imetelstat -
- pimodivir
- lumicitabine
- JNJ-7922
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
ADVERTISEMENT